Dr. Jason Brown explains circulating tumor DNA, and its role in determining immunotherapy effectiveness

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

Dr. Jason Brown discusses emerging research on the effect of microbiomes and genomics on immunotherapy in bladder cancer.

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video series, we are pleased to work with Dr. Shilpa Gupta, Director of the Genitourinary Medical Oncology at TCI and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic

Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Lung Cancer Video Library

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.